Efficacy and safety of tafolecimab in Chinese patients with heterozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled phase 3 trial (CREDIT-2)

Clinical trial by Meng Chai et al. finds that Tafolecimab yields significant and persistent reductions in LDL-C levels and shows a favorable safety profile in patients with Heterozygous familial hypercholesterolemia. Read more about their study here: h